Pfizer "Developing Booster Shot Targeting Delta Variant" (Update)

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] Pfizer announced on the 8th (local time) that it is developing a COVID-19 vaccine booster shot targeting the Delta variant.

In a statement released that day, Pfizer said, as reported by CNBC, "While a third dose of our vaccine is expected to provide the highest preventive effect against most variant viruses, we decided to proceed with this development to avoid any complacency."

The Israeli Ministry of Health announced on the 5th that the efficacy of the Pfizer vaccine, which was 94% against the original coronavirus, sharply dropped to 64% after the spread of the Delta variant.

Pfizer stated, "According to Israeli research, six months after vaccination, when the Delta variant became dominant, vaccine effectiveness was observed to decrease," adding, "This aligns with our Phase 3 clinical trial results."

They further noted, "Considering the data so far, a third dose is likely needed 6 to 12 months after the second dose."

This content was produced with the assistance of AI translation services.